Trial Profile
An Open-Label Phase I/II Safety and Efficacy Study of Itacitinib In Combination With Everolimus In Subjects With Relapsed/Refractory Classical Hodgkin Lymphoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 26 Feb 2024
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Itacitinib (Primary)
- Indications Hodgkin's disease
- Focus Adverse reactions; Therapeutic Use
- Acronyms EVITA
- 20 Feb 2024 Planned End Date changed from 1 Jan 2027 to 1 Jun 2027.
- 17 Feb 2023 Planned primary completion date changed from 1 Jan 2023 to 1 Oct 2024.
- 28 Nov 2022 Planned primary completion date changed from 1 Jan 2026 to 1 Jan 2023.